Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

NCT04890093 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

64

Enrollment

NIH

Sponsor class

Stopped Pending updated agreements in order to enroll additional participants.

Conditions

Sarcoma, Ewing
Rhabdomyosarcoma

Interventions

DRUG: PEN-866
DRUG: Vincristine
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)